OLDWICK, N.J., Sept. 11, 2018 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical
company dedicated to intercepting and preventing immune-mediated
diseases, announced today its Chief Executive Officer Ashleigh Palmer will present at the Janney
Montgomery Scott Healthcare Conference being held September 17-18, 2018, at the Union League Club
in New York City.
Details of Provention's presentation are as follows:
Conference:
|
Janney Montgomery
Scott Healthcare Conference 2018
|
Date:
|
Monday, September 17,
2018
|
Time:
|
8:15 am
(ET)
|
Location:
|
Union League Club,
New York; Bates Room, 3rd Mezzanine
|
An audio webcast will be accessible via the Events and Webcasts
section of the Provention Bio website:
http://investors.proventionbio.com/events. An archive of the audio
will remain available for 90 days following the presentation.
About Provention Bio, Inc.
Provention Bio, Inc. is a
clinical-stage biopharmaceutical company leveraging a
transformational drug development strategy that is focused on the
prevention or interception of immune-mediated disease. Our
diverse portfolio was assembled with product candidates that have
undergone clinical testing but may have been underdeveloped or
deprioritized assets at other companies. Provention's mission is to
in-license, transform and develop clinical-stage, or nearly
clinical-stage, therapeutic candidates targeting the high
morbidity, mortality and escalating costs of autoimmune and
inflammatory diseases including: type 1 diabetes (T1D), Crohn's
disease, ulcerative colitis, lupus, and certain life-threating
viral diseases. For more information on Provention Bio, please
visit www.proventionbio.com.
Forward Looking Statements
Certain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based
on Provention's current expectations and actual results could
differ materially. There are a number of factors that could cause
actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, risks related to failure to obtain FDA approvals or
clearances and noncompliance with FDA regulations; uncertainties of
patent protection and litigation; limited research and development
efforts and dependence upon third parties; substantial competition;
our need for additional financing and the factors listed under
"Risk Factors" in our quarterly report on Form 10-Q for the quarter
ended June 30, 2018 and any
subsequent filings with the Securities and Exchange Commission
(SEC). As with any pharmaceutical under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. Provention does not undertake an
obligation to update or revise any forward-looking statement. The
information set forth herein speaks only as of the date
hereof.
Media & Investor Contacts
Jason Rando / Joshua
Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
T: 212 375 2665 / 212 375 2664
jrando@tiberend.com
jdrumm@tiberend.com
View original
content:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-2018-janney-healthcare-conference-300710106.html
SOURCE Provention Bio, Inc.